​

Spruce Biosciences (SPRB) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

SPRB Stock Forecast

Spruce Biosciences (SPRB) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $137.67, with a high of $150.00 and a low of $123.00. This represents a 217.43% increase from the last price of $43.37.

- $30 $60 $90 $120 $150 High: $150 Avg: $137.67 Low: $123 Last Closed Price: $43.37

SPRB Stock Rating

Spruce Biosciences stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (54.55%), 5 Hold (45.45%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 5 6 Strong Sell Sell Hold Buy Strong Buy

SPRB Price Target Upside V Benchmarks

TypeNameUpside
StockSpruce Biosciences217.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-27
Avg Price Target-$136.50$195.57
Last Closing Price$43.37$43.37$43.37
Upside/Downside-214.73%350.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2616---7
Jun, 2614---5
May, 2614---5
Apr, 2613---4
Mar, 2613---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 16, 2026Debjit ChattopadhyayGuggenheim$123.00$49.91146.44%183.61%
Jun 01, 2026H.C. Wainwright$150.00$51.27192.57%245.86%
Apr 27, 2026Albert LoweCraig-Hallum$140.00$55.63151.66%222.80%
Dec 23, 2025Oppenheimer$283.00$82.82241.70%552.52%
Nov 11, 2025JMP Securities$259.00$115.61124.03%497.19%
Oct 28, 2025JMP Securities$254.00$123.02106.47%485.66%
Oct 21, 2025Leerink Partners$160.00$134.0019.40%268.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 13, 2026B. RileyBuyinitialise
Jun 16, 2026GuggenheimBuyinitialise
May 27, 2026OppenheimerOutperformOutperformhold
Apr 27, 2026Craig-HallumBuyinitialise
Feb 19, 2026H.C. WainwrightBuyBuyhold
Dec 23, 2025OppenheimerOutperformOutperforminitialise
Nov 11, 2025CitigroupOutperformOutperformhold
Nov 11, 2025CitigroupMarket PerformMarket Performhold
Oct 28, 2025CitigroupOutperformupgrade
Dec 02, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-100 $-80 $-60 $-40 $-20 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-93.00$-96.75$-50.83---
Avg Forecast$-1.40$-0.93$-0.57$-0.62$-0.93$-1.01
High Forecast$-1.30$-0.84$-0.41$-0.15$-0.33$-0.35
Low Forecast$-1.50$-1.07$-0.68$-1.09$-1.53$-1.66
Surprise %6542.86%10303.23%8817.54%---

Revenue Forecast

$0 $6M $12M $18M $24M $30M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.09M$4.91M----
Avg Forecast$8.53M$5.09M$900.00K$8.25M$10.75M$19.50M
High Forecast$9.97M$5.60M$1.35M$12.38M$16.13M$29.25M
Low Forecast$7.40M$4.51M$450.00K$4.13M$5.38M$9.75M
Surprise %18.29%-3.58%----

Net Income Forecast

$-65M $-53M $-41M $-29M $-17M $-5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-47.92M$-53.04M----
Avg Forecast$-53.79M$-39.43M$-25.61M$-36.13M$-35.81M$-38.70M
High Forecast$-49.97M$-32.37M$-15.75M$-5.65M$-12.54M$-13.55M
Low Forecast$-57.60M$-41.36M$-26.34M$-41.84M$-59.09M$-63.86M
Surprise %-10.91%34.52%----

SPRB Forecast FAQ

Is Spruce Biosciences stock a buy?

Spruce Biosciences stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Spruce Biosciences is a favorable investment for most analysts.

What is Spruce Biosciences's price target?

Spruce Biosciences's price target, set by 11 Wall Street analysts, averages $137.67 over the next 12 months. The price target range spans from $123 at the low end to $150 at the high end, suggesting a potential 217.43% change from the previous closing price of $43.37.

How does Spruce Biosciences stock forecast compare to its benchmarks?

Spruce Biosciences's stock forecast shows a 217.43% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Spruce Biosciences over the past three months?

  • July 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Spruce Biosciences’s EPS forecast?

Spruce Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.62, marking a -98.78% decrease from the reported $-50.83 in 2025. Estimates for the following years are $-0.93 in 2027, and $-1.01 in 2028.

What is Spruce Biosciences’s revenue forecast?

Spruce Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $8.25M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $10.75M, and $19.5M for 2028.

What is Spruce Biosciences’s net income forecast?

Spruce Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-36.125M, representing a 0% decrease from the reported $0 in 2025. Projections indicate $-35.815M in 2027, and $-38.703M in 2028.